NEWS COMMENTARY

L'Oréal partners with bacteriophage company Micreos for skin microbiome applications

Published:
November 12, 2020
Services:
Chemicals More...
Activities:
Licensing
Average importance

Through this licensing agreement, L'Oréal will gain access to Micreos' endolysin technology for cosmetic and skin care applications. Micreos develops the "Staphefekt" endolysin, which is a phage enzyme that selectively kills Staphylococcus aureus bacteria. The company has already commercialized its endolysin-containing Gladskin product for a number of skin conditions. While several players in the skin microbiome space focus on the use of probiotics, this partnership will help L'Oréal explore the applicability of phage-based solutions for skin care applications. As the skin microbiome space evolves further, we expect to see more players in the cosmetics industry value chain getting involved through such partnerships for product development.

For the original news article, click here .


Further Reading

Microbiome-based Business Opportunities for Consumer Products

State of the Market Report | September 30, 2021

Over the past decade, microbiome research has accelerated, and this space has emerged as a hotspot for innovation, given its potential to impact a number of industries in the agrifood and health value chain. Despite staggering startup activity, developers have barely scratched the surface when it ... Not part of subscription

Industry Event Recap: Key takeaways from Probiota 2021

Analyst Insight | February 25, 2021

This year's Probiota Europe event took place virtually and brought together global experts from industry and academia to discuss the present and the future of microbiome modulation through ‑biotics for consumer health. Lux presented at the event and participated in a panel discussion about the ... Not part of subscription

Lactobio

Company Snapshot | September 02, 2021

The company was founded by Søren Kjærulff, who previously founded another startup, FermBiotics, and served as senior director of biopharma R&D at Novozymes. The company raised about $1.3 million in a funding round in March 2021; in May 2021, it received another grant from Innovation Fund Denmark... Not part of subscription